尿路上皮癌的一例报告及文献复习
A Case Report and Literature Review of Urothelial Carcinoma
摘要: 背景:众所周知,转移性膀胱癌是膀胱癌的晚期表现。临床上一般认为其转移主要通过淋巴管或血液循环进行,但直接浸润直肠并有直肠环形收缩表现的病例却较为少见。病例介绍:本文报告了1例67岁男性,无明显诱因出现大便梗阻,小便失禁,行肠镜下取组织活检,病理提示转移性尿路上皮癌可能性大,在我科进行膀胱镜检查 + 膀胱肿瘤活检术,术后病理示高级别浸润性尿路上皮癌,后通过腹腔镜下输尿管皮肤造口术及结肠造口术成功进行手术治疗。结论:晚期转移性膀胱癌的诊断至关重要,患者的初始症状并不一定与泌尿系统相关。充分的辅助检查对明确诊断以及制定完善的诊疗方案具有很大的帮助。
Abstract: Background: It is well known that metastatic bladder cancer represents an advanced stage of the disease. Clinically, metastasis is generally considered to occur via lymphatic or hematogenous dissemination; however, cases demonstrating direct rectal invasion with annular rectal stricture are relatively rare. Case Presentation: This article reports a 67-year-old male who developed bowel obstruction and urinary incontinence without obvious predisposing factors. Colonoscopic biopsy suggested a high probability of metastatic urothelial carcinoma. Subsequent cystoscopy with bladder tumor biopsy in our department revealed high-grade invasive urothelial carcinoma on pathological examination. The patient successfully underwent laparoscopic ureterocutaneostomy and colostomy. Conclusion: Timely diagnosis of advanced metastatic bladder cancer is critical, as initial symptoms may not be urologically specific. Comprehensive auxiliary examinations are essential for accurate diagnosis and multidisciplinary treatment planning.
文章引用:祁艺新, 刘昌勋, 董大海, 王科, 杨晓坤. 尿路上皮癌的一例报告及文献复习[J]. 临床医学进展, 2025, 15(6): 632-638. https://doi.org/10.12677/acm.2025.1561770

参考文献

[1] Siegel, R.L., Miller, K.D. and Jemal, A. (2018) Cancer Statistics, 2018. CA: A Cancer Journal for Clinicians, 68, 7-30. [Google Scholar] [CrossRef] [PubMed]
[2] Liu, G.X., Liu, P. and Tang, C. (2012) Relationship between NUSAP1 Expression and Lymph Node Metastasis in Bladder Urothelial Carcinoma. Western Medicine, 34, 240-244.
[3] Dobruch, J. and Oszczudłowski, M. (2021) Bladder Cancer: Current Challenges and Future Directions. Medicina, 57, Article 749. [Google Scholar] [CrossRef] [PubMed]
[4] Patel, V.G., Oh, W.K. and Galsky, M.D. (2020) Treatment of Muscle‐Invasive and Advanced Bladder Cancer in 2020. CA: A Cancer Journal for Clinicians, 70, 404-423. [Google Scholar] [CrossRef] [PubMed]
[5] Langenstroer, P., Zacharias, A., Almagro, U. and Dewire, D. (1996) Annular Constriction of the Rectum Secondary to Transitional Cell Carcinoma of the Bladder. Urology, 47, 442-444. [Google Scholar] [CrossRef] [PubMed]
[6] Saitoh, H., Hida, M., Wakabayashi, T., Iida, T. and Satoh, T. (1982) Metastasis of Urothelial Tumors of the Bladder: Correlation between Sites and Number of Organs Involved. The Tokai Journal of Experimental and Clinical Medicine, 7, 517-526.
[7] Takeuchi, H., Tokuyama, N., Kuroda, I. and Aoyagi, T. (2016) Annular Rectal Constriction Caused by Infiltrating Bladder Cancer: A Case Report. Molecular and Clinical Oncology, 5, 842-844. [Google Scholar] [CrossRef] [PubMed]
[8] Stillwell, T.J., Rife, C.C. and Lieber, M.M. (1989) Bladder Carcinoma Presenting with Rectal Obstruction. Urology, 34, 238-240. [Google Scholar] [CrossRef] [PubMed]
[9] Ito, Y., Nishimoto, K., Ogata, K. and Fujioka, T. (2008) [Annular Constriction of the Rectum Secondary to Urothelial Carcinoma of the Bladder]. Hinyokika Kiyo, 54, 553-555.
[10] Kobayashi, S., Kato, H., Iijima, K., Kinebuchi, Y., Igawa, Y. and Nishizawa, O. (2006) Annular Rectal Constriction Due to Infiltration by Bladder Cancer. Hinyokika Kiyo, 52, 569-572.
[11] Cathomas, R., Lorch, A., Bruins, H.M., Compérat, E.M., Cowan, N.C., Efstathiou, J.A., et al. (2022) The 2021 Updated European Association of Urology Guidelines on Metastatic Urothelial Carcinoma. European Urology, 81, 95-103. [Google Scholar] [CrossRef] [PubMed]
[12] Moch, H., Amin, M.B., Berney, D.M., Compérat, E.M., Gill, A.J., Hartmann, A., et al. (2022) The 2022 World Health Organization Classification of Tumours of the Urinary System and Male Genital Organs—Part A: Renal, Penile, and Testicular Tumours. European Urology, 82, 458-468. [Google Scholar] [CrossRef] [PubMed]
[13] Christensen, E., Birkenkamp-Demtröder, K., Nordentoft, I., Høyer, S., van der Keur, K., van Kessel, K., et al. (2017) Liquid Biopsy Analysis of FGFR3 and PIK3CA Hotspot Mutations for Disease Surveillance in Bladder Cancer. European Urology, 71, 961-969. [Google Scholar] [CrossRef] [PubMed]
[14] Korkes, F., Fernandes, E., Gushiken, F.A., Glina, F.P.A., Baccaglini, W., Timóteo, F., et al. (2022) Bricker Ileal Conduit Vs. Cutaneous Ureterostomy after Radical Cystectomy for Bladder Cancer: A Systematic Review. International braz j urol, 48, 18-30. [Google Scholar] [CrossRef] [PubMed]
[15] Gakis, G., Efstathiou, J., Lerner, S.P., Cookson, M.S., Keegan, K.A., Guru, K.A., et al. (2013) ICUD-EAU International Consultation on Bladder Cancer 2012: Radical Cystectomy and Bladder Preservation for Muscle-Invasive Urothelial Carcinoma of the Bladder. European Urology, 63, 45-57. [Google Scholar] [CrossRef] [PubMed]
[16] Powles, T., Park, S.H., Voog, E., Caserta, C., Valderrama, B.P., Gurney, H., et al. (2020) Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma. New England Journal of Medicine, 383, 1218-1230. [Google Scholar] [CrossRef] [PubMed]
[17] Loriot, Y., Necchi, A., Park, S.H., Garcia-Donas, J., Huddart, R., Burgess, E., et al. (2019) Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma. New England Journal of Medicine, 381, 338-348. [Google Scholar] [CrossRef] [PubMed]
[18] Bellmunt, J., de Wit, R., Vaughn, D.J., Fradet, Y., Lee, J., Fong, L., et al. (2017) Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma. New England Journal of Medicine, 376, 1015-1026. [Google Scholar] [CrossRef] [PubMed]
[19] Powles, T., Csőszi, T., Özgüroğlu, M., Matsubara, N., Géczi, L., Cheng, S.Y., et al. (2021) KEYNOTE-361 Investigators. Pembrolizumab Alone or Combined with Chemotherapy versus Chemotherapy as First-Line Therapy for Advanced Urothelial Carcinoma (KEYNOTE-361): A Randomised, Open-Label, Phase 3 Trial. The Lancet Oncology, 22, 931-945.
[20] Fry, D.E., Amin, M. and Harbrecht, P.J. (1979) Rectal Obstruction Secondary to Carcinoma of the Prostate. Annals of Surgery, 189, 488-492.
[21] Miettinen, M., McCue, P.A., Sarlomo-Rikala, M., Rys, J., Czapiewski, P., Wazny, K., et al. (2014) GATA3: A Multi-Specific but Potentially Useful Marker in Surgical Pathology: A Systematic Analysis of 2500 Epithelial and Nonepithelial Tumors. American Journal of Surgical Pathology, 38, 13-22. [Google Scholar] [CrossRef] [PubMed]